Clinical trial
Low Dose Danazol for the Treatment of Telomere Related Diseases
NCT03312400 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Low Dose Danazol for the Treatment of Telomere Related Diseases
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 8, 2018
- Completion date
- October 31, 2025
- Enrollment
- 18 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
telomere disease